ABCG2 polymorphisms and susceptibility to ARV‐associated hepatotoxicity

Abstract

Abstract Background The ABCG2 421C/A polymorphism contributes significantly to the distribution and absorption of antiretroviral (ARV) regimens and is associated with the undesirable side effects of efavirenz. Methods To investigate this, we examined ABCG2 34G/A (rs2231137) and 421C/A (rs2231142) genetic variations in 149 HIV‐infected patients (116 without hepatotoxicity, 33 with ARV‐induced hepatotoxicity) and 151 healthy controls through the PCR‐restriction fragment length polymorphism (PCR‐RFLP) technique. Results and Discussion The ABCG2 34GA genotype and 34A allele indicated a risk for antiretroviral therapy‐associated hepatotoxicity development (p = 0.09, OR = 1.58, 95% CI: 0.93–2.69; p = 0.06, OR = 1.50, 95% CI: 0.98–2.30). The haplotype GA was associated with hepatotoxicity (p = 0.042, OR = 2.37, 95% CI: 1.04–5.43; p = 0.042, OR = 2.49, 95% CI: 1.04–5.96). Moreover, when comparing HIV patients with hepatotoxicity to healthy controls, the haplotype GA had an association with an elevated risk for the development of hepatotoxicity (p = 0.041, OR = 1.73, 95% CI: 1.02–2.93). Additionally, the association of the ABCG2 34GA genotype with the progression of HIV (p = 0.02, OR = 1.97, 95% CI: 1.07–3.63) indicated a risk for advanced HIV infection. Furthermore, the ABCG2 421AA genotype was linked to tobacco users and featured as a risk factor for the progression of HIV disease (p = 0.03, OR = 11.07, 95% CI: 1.09–270.89). Conclusion The haplotype GA may enhance the risk of hepatotoxicity development and its severity. Individuals with the ABCG2 34A allele may also be at risk for the development of hepatotoxicity. Additionally, individuals with an advanced stage of HIV and the ABCG2 34GA genotype may be at risk for disease progression.

Keywords

• ABCG2 polymorphism
• ARV‐associated hepatotoxicity
• genetic susceptibility
• haplotypes
• HIV patients